Companies whose shares are expected to trade actively in today’s session are Ascena Retail Group Inc (NASDAQ:ASNA), Impax Laboratories Inc (NASDAQ:IPXL), Williams Partners L.P. (NYSE:WPZ), J.C. Penney Company, Inc. (NYSE:JCP), Santarus, Inc. (NASDAQ:SNTS) and Zoltek Companies, Inc. (NASDAQ:ZOLT).
Ascena Retail Group Inc (NASDAQ:ASNA): The women’s apparel retailer’s second quarter earnings declined less than what analysts had expected, and the company is holding firm on its full year guidance. Ascena’s core businesses are now stabilizing, and new divisions have shown improvements. Shares rose 13.67 percent to $18.79 in early trading session.
Impax Laboratories Inc (NASDAQ:IPXL): The U.S. FDA officials have found continuing problems at the pharmaceutical company’s Hayward, Calif., manufacturing facility. The problems may negatively affect Impax’s pending and new drug applications. Shares plunged 25 percent to $15 in the early session.
Williams Partners L.P. (NYSE:WPZ): The energy company announced to offer 10 million units that represent limited partnership interests. Additionally, it will also sell about 3 million units in a private placement to its affiliate Williams Cos.. The company will use the proceeds to pay off debts. Williams Partners is estimated have to 411 million outstanding units after the offering. Shares slid 3.28 percent to $48.90 in the early session.
J.C. Penney Company, Inc. (NYSE:JCP): Vornado Realty trust announced to dump over 40 percent of its stake in the department store chain, reducing its losses on the J.C Penney’s disappointing performance. Shares slid 5.73 percent to $15.78 in the early session.
Santarus, Inc. (NASDAQ:SNTS): The bio-pharmaceutical company’s fourth quarter profits nearly tripled amid double digit revenue growth. The company also issued an optimistic earnings guidance for the current year. Shares soared 8.59 percent to $14.98 in early trading.
Zoltek Companies, Inc. (NASDAQ:ZOLT): Quinpario Partners LLC, which owns 10 percent stake in the carbon fibers manufacturer, seeks to remove all the Zoltek directors. The company has been underperforming financially and commercially. Shares rose 25.41 percent to $11.60 in early market trading.